Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 2, 2006, Pages 229-237

  Bannister, Wendy P ^a   Kirk, Ole ^b   Gatell, Jose M ^c   Knysz, Brygida ^d   Viard, Jean Paul ^e   Mens, Helene ^b   Monforte, Antonella D'Arminio ^f   Phillips, Andrew N ^a   Mocroft, Amanda ^a   Lundgren, Jens D ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HVIDOVRE HOSPITAL   (Denmark)

^c HOSPITAL CLÍNIC   (Spain)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiretroviral naive; Combination antiretroviral therapy; Geographic regions; Time trends; Virologic response

Indexed keywords

ARTICLE; CONTROLLED STUDY; EUROPE; FEMALE; GEOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TIME; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; TIME FACTORS; VIRAL LOAD;

EID: 33745092805     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000214815.95786.31     Document Type: Article

References (35)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
2. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ. 1997;315:1194-1199.
3. Hogg RS, Heath KV, Yip B, Craib KJP, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454.
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
5. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet. 2000;356:291-296.
6. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
7. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS USA panel. JAMA. 2004;292:251-265.
8. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK, Panel on Clinical Practices for the Treatment of HIV.Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep. 2002;51:1-55.
9. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med. 1996;334:1011-1017.
10. Gulick R, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
11. Cameron DW, Chiozzi M, Danner S, et al. Randomised placebo controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351:543-549.
12. Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2004;23:360-361.
13. Wood E, Hogg RS, Yip B, et al. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:261-268.
14. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
15. Heath KV, Singer J, O'Shaughnessy MV, et al. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:211-217.
16. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-I drug resistance among recently infected persons. JAMA. 2002;288:181-188.
17. Cane P, Chrystie I, Dunn D, et al. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ. 2001;322:1087-1088.
18. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, et al. Changes over time in risk of initial virological failure of combination antiretroviral treatment. A multi-cohort analysis, 1996 to 2002. Arch Intern Med. In press.
19. Kirk O, Mocroft A, Katzenstein TL, et al. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS. 1998;12:2031-2039.
20. Chiesi A, Mocroft A, Dally LG, et al. Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. AIDS. 1999;13:2281-2288.
21. Mocroft A, Miller V, Chiesi A, et al. Virological failure among patients on HAART from across Europe; results from the EuroSIDA study. Antivir Ther. 2000;5:107-112.
22. EuroSIDA. A multicentre study: tracking HIV/AIDS across Europe 2003. Hvidovre, Denmark, Copenhagen HIV Programme, 2003. Available at: http://www.cphiv.dk. Accessed January 5, 2006.
23. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:1-19.
24. Johnson VA, Vézinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D. Update of the drug resistance mutations in HIV-1: fall 2005. Top HIV Med. 2005;13:125-131.
25. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-2303.
26. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304-2315.
27. Walmsley S, Bernstein B, King M, et al.Ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
28. Staszewski S, Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudrne, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
29. Perry CM, Noble S.Saquinavir soft-gel capsule formulation: a review of its use in patients with HIV infection. Drugs. 1998;55:461-486.
30. Yerly S, Kaiser L, Race E, et al. Transmission of antiretroviral-drug- resistant HIV-1 variants. Lancet. 1999;354:729-733.
31. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
32. Zennou V, Mammano F, Paulous S, et al. Loss of viral fitness associated with multiple gag and gag-pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol. 1998;72:3300-3306.
33. Picado J, Savara AV, Sutton L, et al. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999;73:3744-3752.
34. The EuroGuidelines Group for HIV Resistance.Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS. 2001;15:309-320.
35. Kirk O, Lundgren JD.Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines. Curr Opin Infect Dis. 2004;17:33-37.